Login / Signup

Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy.

Yuki HatayamaToru MotokuraYuzuru HosodaSayaka SuzukiHiroya NambaKonami KatoNao KojimaTakuya HorieTakuya IwamotoNoriko YamashitaHitomi IchikawaTetsuya Fukuda
Published in: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2022)
The regression models can estimate the FVIII:C levels in patients with HA receiving emicizumab and would be useful in a bleeding emergency and/or surgery.
Keyphrases
  • minimally invasive
  • emergency department
  • public health
  • coronary artery bypass
  • healthcare
  • atrial fibrillation
  • stem cells
  • surgical site infection
  • acute coronary syndrome
  • cell therapy
  • data analysis